

Supporting Information

Intact Quantitation and Evaluation of a PEG-Glycosulfopeptide as a Therapeutic P-Selectin Antagonist

Diane D. Park^{1,2}, Simon S. Park^{1,2}, Erbin Dai^{1,2}, Carolyn A. Haller^{1,2}, Daniel J. Wong^{1,2}, Walter J. Wever^{1,2}, Richard D. Cummings^{1,3}, Elliot L. Chaikof^{1,2,3,4*}

¹Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave, Boston, MA 02215

²Wyss Institute for Biologically Inspired Engineering, Harvard University, 3 Blackfan Circle, Boston, MA 02115

³Harvard Medical School Center for Glycoscience, Harvard Medical School, Boston, MA 02215

⁴Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139

***Address correspondence to:**

Elliot L. Chaikof, MD, PhD
Department of Surgery
Beth Israel Deaconess Medical Center
110 Francis Street, Suite 9F
Boston, MA 02115
Tel: (617) 632-9581; Fax: (617) 632-9701
E-mail: echaikof@bidmc.harvard.edu

Supplementary Figures

Figure S1. Schematic of the flow path of the ultra-high performance liquid chromatography-mass spectrometry (UHPLC-MS) system designed for the analysis of high molecular mass analytes in aqueous solutions using hydrophilic interaction liquid chromatography (HILIC). (A) Configuration of HILIC-MS during sample loading. (B) Configuration of HILIC-MS during elution and intact MS analysis.

Figure S2. Mass spectrometric analysis of PEG10-GSnP-6 under various analytical conditions. Deconvoluted mass spectra of PEG10-GSnP-6 analyzed using (A) butylene carbonate as an additive, (B) 5 mM ammonium acetate/acetic acid (pH 3.8) solvent system with the ion transfer temperature at 275°C, (C) 5 mM ammonium formate/ammonia (pH 8.3) solvent system with MS resolution at 240,000.

Figure S3. Analysis of intact, reduced alpha synuclein in solution. (A) Extracted chromatogram using HILIC. (B) Deconvoluted full mass spectrum. (C) Detected charged states using ESI-Orbitrap-MS.

Figure S4. Analysis of intact, reduced thioredoxin in solution. (A) Extracted chromatogram using HILIC. (B) Deconvoluted full mass spectrum. (C) Detected charged states using ESI-Orbitrap-MS.

Figure S5. Analysis of intact ubiquitin in solution. (A) Extracted chromatogram using HILIC. (B) Deconvoluted full mass spectrum. (C) Detected charged states using ESI-Orbitrap-MS.

Figure S6. Analysis of intact aprotinin in solution. (A) Extracted chromatogram using HILIC. (B) Deconvoluted full mass spectrum. (C) Detected charged states using ESI-Orbitrap-MS.

Figure S7. Analysis of intact enfuvirtide in solution. (A) Extracted chromatogram using HILIC. (B) Deconvoluted full mass spectrum. (C) Detected charged states using ESI-Orbitrap-MS.

Figure S8. Analysis of intact, sulfated big gastrin in solution. (A) Extracted chromatogram using HILIC. (B) Deconvoluted full mass spectrum. (C) Detected charged states using ESI-Orbitrap-MS.

Figure S9. Reproducibility of retention times following multiple injections of PEG10-GSnP-6 extracted from spiked plasma.

Figure S10. MS/MS spectrum of a native murine plasma protein employing higher-energy collisional dissociation (HCD) with stepped collision energies (20,30,40) in negative mode.

Figure S11. MS/MS spectrum of a native murine urine protein employing higher-energy collisional dissociation (HCD) with stepped collision energies (10,20,30) in negative mode.

Figure S12. Binding of U-937 cells to human P-selectin-Fc chimera assessed by flow cytometry. Binding was detected by PE-conjugated anti-Fc. (A) Determination of optimal P-selectin-Fc chimera to 300,000 U-937 cells. U-937 cells incubated without P-selectin displayed no binding. (B-C) Inhibition of binding by anti-PSGL-1 (1:5), anti-P-selectin (2 µg), or EDTA (20 mM). Representative histograms are shown from 3 experiments.

Figure S1.




Figure S2.




Figure S3.




Figure S4.




Figure S5.




Figure S6.




Figure S7.




Figure S8.




Figure S9.




Figure S10.




Figure S11.






Figure S12.

A



B



C

